Upstream Bio

Upstream Bio company information, Employees & Contact Information

Explore related pages

Related company profiles:

We are advancing verekitug, a clinical-stage monoclonal antibody targeting an upstream driver of inflammatory response. Our experienced team is committed to leveraging verekitug’s unique mechanism of action to improve the treatment options for millions of patients living with severe inflammatory diseases.

Company Details

Employees
66
Founded
-
Address
890 Winter St,
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Waltham, Massachusetts
Looking for a particular Upstream Bio employee's phone or email?

Upstream Bio Questions

News

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress - Yahoo Finance

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress Yahoo Finance

Upstream Bio to Host Conference Call and Webcast to Report - GlobeNewswire

Upstream Bio to Host Conference Call and Webcast to Report GlobeNewswire

Upstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory Portfolio - Nasdaq

Upstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory Portfolio Nasdaq

24-Week TSLP Inhibition: Upstream Bio's Verekitug Shows Breakthrough Respiratory Disease Treatment Data - Stock Titan

24-Week TSLP Inhibition: Upstream Bio's Verekitug Shows Breakthrough Respiratory Disease Treatment Data Stock Titan

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress - Yahoo Finance

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress Yahoo Finance

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum - GlobeNewswire

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum GlobeNewswire

Upstream Bio Appoints Allison Ambrose as General Counsel - citybiz

Upstream Bio Appoints Allison Ambrose as General Counsel citybiz

76% Less Surgery Need: Upstream Bio's Nasal Polyp Drug Verekitug Shows Breakthrough Phase 2 Results - Stock Titan

76% Less Surgery Need: Upstream Bio's Nasal Polyp Drug Verekitug Shows Breakthrough Phase 2 Results Stock Titan

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - Yahoo Finance

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Yahoo Finance

Upstream Bio, two other U.S. biotech startups price IPOs as healthcare listings rise - Reuters

Upstream Bio, two other U.S. biotech startups price IPOs as healthcare listings rise Reuters

Chronic rhinosinusitis with nasal polyps improves in 24 weeks with two verekitug doses - Healio

Chronic rhinosinusitis with nasal polyps improves in 24 weeks with two verekitug doses Healio

Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference - Yahoo Finance

Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference Yahoo Finance

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights GlobeNewswire

Upstream Bio (UPB): Assessing Valuation as Shares Climb 7% Over the Past Week - Yahoo Finance

Upstream Bio (UPB): Assessing Valuation as Shares Climb 7% Over the Past Week Yahoo Finance

Upstream Bio Announces Addition to Russell 2000® Index - GlobeNewswire

Upstream Bio Announces Addition to Russell 2000® Index GlobeNewswire

Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Yahoo Finance

Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights Yahoo Finance

First subject dosed in Upstream Bio’s Phase II trial of verekitug for COPD - Clinical Trials Arena

First subject dosed in Upstream Bio’s Phase II trial of verekitug for COPD Clinical Trials Arena

Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress - Nasdaq

Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress Nasdaq

Upstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2 - Business Wire

Upstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2 Business Wire

Upstream Bio Initiates Phase 2 Clinical Trial for COPD Drug, Verekitug - Yahoo Finance

Upstream Bio Initiates Phase 2 Clinical Trial for COPD Drug, Verekitug Yahoo Finance

Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases - Business Wire

Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases Business Wire

Upstream Bio Reports Positive Top-line Results From Phase 2 VIBRANT Study - Nasdaq

Upstream Bio Reports Positive Top-line Results From Phase 2 VIBRANT Study Nasdaq

Upstream Bio raises $200M in fresh funding for asthma drug - BioPharma Dive

Upstream Bio raises $200M in fresh funding for asthma drug BioPharma Dive

Upstream Bio valued at $1.1 bln in stellar debut as healthcare IPOs heat up - Reuters

Upstream Bio valued at $1.1 bln in stellar debut as healthcare IPOs heat up Reuters

Upstream Bio’s Quest for Effective Best-in-Class Treatments for Allergic Inflammation - BioSpace

Upstream Bio’s Quest for Effective Best-in-Class Treatments for Allergic Inflammation BioSpace

Upstream Bio shares soar in impressive IPO - The Pharma Letter

Upstream Bio shares soar in impressive IPO The Pharma Letter

Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M - MedCity News

Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M MedCity News

Upstream Bio, a richly funded startup, reveals its lead drug and research plans - BioPharma Dive

Upstream Bio, a richly funded startup, reveals its lead drug and research plans BioPharma Dive

Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent - Seeking Alpha

Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent Seeking Alpha

Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team - Business Wire

Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team Business Wire

Upstream Bio Dives into Severe Asthma Space with $200M in Series A Financing - BioSpace

Upstream Bio Dives into Severe Asthma Space with $200M in Series A Financing BioSpace

Upstream Bio Raises $200M in Series A Financing - FinSMEs

Upstream Bio Raises $200M in Series A Financing FinSMEs

Top Upstream Bio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant